.Attributes Medicine, Published online: thirteen September 2024 doi:10.1038/ s41591-024-03261-7In the non-randomized stage 3b/4 DESTINY-Breast12 research, trastuzumab deruxtecan (T-DXd) treatment of individuals along with HER2+ sophisticated bosom cancer cells as well as active or even secure brain metastases revealed consistent intracranial task and also wide spread efficiency of T-DXd.